Yeast reveals similar molecular mechanisms underlying alpha- and beta-synuclein toxicity.

Synucleins belong to a family of intrinsically unstructured proteins that includes alpha-synuclein (aSyn), beta-synuclein (bSyn) and gamma-synuclein (gSyn). aSyn is the most studied member of the synuclein family due to its central role in genetic and sporadic forms of Parkinson's disease and other neurodegenerative disorders known as synucleionopathies. In contrast, bSyn and gSyn have been less studied, but recent reports also suggest that, unexpectedly, these proteins may also cause neurotoxicity. Here, we explored the yeast toolbox to investigate the cellular effects of bSyn and gSyn. We found that bSyn is toxic and forms cytosolic inclusions that are similar to those formed by aSyn. Moreover, we found that bSyn shares similar toxicity mechanisms with aSyn, including vesicular trafficking impairment and induction of oxidative stress. We demonstrate that co-expression of aSyn and bSyn exacerbates cytotoxicity, due to increased dosage of toxic synuclein forms, and that they are able to form heterodimers in both yeast and in human cells. In contrast, gSyn is not toxic and does not form inclusions in yeast cells. Altogether, our findings shed light into the question of whether bSyn can exert toxic effects and confirms the occurrence of aSyn/bSyn heterodimers, opening novel perspectives for the development of novel strategies for therapeutic intervention in synucleinopathies.

[1]  A. Sekigawa,et al.  Role of α- and β-Synucleins in the Axonal Pathology of Parkinson’s Disease and Related Synucleinopathies , 2015, Biomolecules.

[2]  D. Stewart,et al.  (Poly)phenols protect from α-synuclein toxicity by reducing oxidative stress and promoting autophagy. , 2015, Human molecular genetics.

[3]  T. Hortobágyi,et al.  Gamma-synuclein pathology in amyotrophic lateral sclerosis , 2014, Annals of clinical and translational neurology.

[4]  O. Hantschel,et al.  C-abl Phosphorylates Alpha-synuclein And Regulates Its Degradation, Implication For Alpha-synuclein Clearance And Contribution To The Pathogenesis Of Parkinson's Disease , 2014 .

[5]  S. Chandra,et al.  Synucleins Regulate the Kinetics of Synaptic Vesicle Endocytosis , 2014, The Journal of Neuroscience.

[6]  S. Tenreiro,et al.  Phosphorylation Modulates Clearance of Alpha-Synuclein Inclusions in a Yeast Model of Parkinson's Disease , 2014, PLoS genetics.

[7]  S. Tenreiro,et al.  Protein phosphorylation in neurodegeneration: friend or foe? , 2014, Front. Mol. Neurosci..

[8]  E. Masliah,et al.  c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. , 2014, Human molecular genetics.

[9]  Sandra Tenreiro,et al.  Harnessing the power of yeast to unravel the molecular basis of neurodegeneration , 2013, Journal of neurochemistry.

[10]  Jasper Akerboom,et al.  β‐synuclein aggregates and induces neurodegeneration in dopaminergic neurons , 2013, Annals of neurology.

[11]  E. Masliah,et al.  The many faces of α-synuclein: from structure and toxicity to therapeutic target , 2012, Nature Reviews Neuroscience.

[12]  A. Sekigawa,et al.  Possible Alterations in β-Synuclein, the Non-Amyloidogenic Homologue of α-Synuclein, during Progression of Sporadic α-Synucleinopathies , 2012, International journal of molecular sciences.

[13]  E. Masliah,et al.  Suppression of α-synuclein toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast depends on genetic context. , 2012, Human molecular genetics.

[14]  Nicolas L. Fawzi,et al.  A rigid disulfide-linked nitroxide side chain simplifies the quantitative analysis of PRE data , 2011, Journal of biomolecular NMR.

[15]  S. Inoue,et al.  A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain , 2010, Nature communications.

[16]  S. Chandra,et al.  αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction , 2010, Proceedings of the National Academy of Sciences.

[17]  J. Baum,et al.  Detection of transient interchain interactions in the intrinsically disordered protein alpha-synuclein by NMR paramagnetic relaxation enhancement. , 2010, Journal of the American Chemical Society.

[18]  E. Masliah,et al.  Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits α-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions , 2010, The Journal of Neuroscience.

[19]  Joshua A. Kritzer,et al.  Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models , 2010, Disease Models & Mechanisms.

[20]  E. Masliah,et al.  Lovastatin ameliorates α-synuclein accumulation and oxidation in transgenic mouse models of α-synucleinopathies , 2010, Experimental Neurology.

[21]  E. Masliah,et al.  Phosphorylation of Synucleins by Members of the Polo-like Kinase Family* , 2009, The Journal of Biological Chemistry.

[22]  D. Moore,et al.  Clearance and Phosphorylation of Alpha-Synuclein Are Inhibited in Methionine Sulfoxide Reductase A Null Yeast Cells , 2009, Journal of Molecular Neuroscience.

[23]  U. Pettersson Faculty Opinions recommendation of Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. , 2009 .

[24]  J. Trojanowski,et al.  Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration , 2008, The Journal of Neuroscience.

[25]  B. Hyman,et al.  CHIP Targets Toxic α-Synuclein Oligomers for Degradation* , 2008, Journal of Biological Chemistry.

[26]  Bradley T. Hyman,et al.  Formation of Toxic Oligomeric α-Synuclein Species in Living Cells , 2008, PloS one.

[27]  U. Banerjee,et al.  A protocol for in vivo detection of reactive oxygen species , 2008 .

[28]  S. Lindquist,et al.  The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis , 2008, Proceedings of the National Academy of Sciences.

[29]  J. Trojanowski,et al.  Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. , 2007, Molecular biology of the cell.

[30]  S. Lindquist,et al.  A suite of Gateway® cloning vectors for high‐throughput genetic analysis in Saccharomyces cerevisiae , 2007, Yeast.

[31]  E. Masliah,et al.  Enhanced Lysosomal Pathology Caused by β-Synuclein Mutants Linked to Dementia with Lewy Bodies* , 2007, Journal of Biological Chemistry.

[32]  C. Griesinger,et al.  Structural characterization of the intrinsically unfolded protein β-synuclein, a natural negative regulator of α-synuclein aggregation , 2007 .

[33]  John Q. Trojanowski,et al.  -synuclein modulates -synuclein neurotoxicity by reducing -synuclein protein expression , 2006 .

[34]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[35]  A. Linstedt Faculty Opinions recommendation of Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. , 2006 .

[36]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[37]  C. A. Froelich,et al.  Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. , 2005, Journal of molecular biology.

[38]  C. Ross,et al.  α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.

[39]  Wayne Boucher,et al.  The CCPN data model for NMR spectroscopy: Development of a software pipeline , 2005, Proteins.

[40]  Vladimir N. Uversky,et al.  Forcing Nonamyloidogenic β-Synuclein To Fibrillate† , 2005 .

[41]  M. Feany,et al.  α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.

[42]  J. Winderickx,et al.  Characterization of α‐synuclein aggregation and synergistic toxicity with protein tau in yeast , 2005 .

[43]  C. Griesinger,et al.  Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Masliah,et al.  An antiaggregation gene therapy strategy for Lewy body disease utilizing β-synuclein lentivirus in a transgenic model , 2004, Gene Therapy.

[45]  M. Farrer,et al.  α‐Synuclein promoter confers susceptibility to Parkinson's disease , 2004 .

[46]  J. Trojanowski,et al.  β-Synuclein gene alterations in dementia with Lewy bodies , 2004, Neurology.

[47]  Y. Teo,et al.  Alpha-synuclein haplotypes implicated in risk of Parkinson’s disease , 2004, Neurology.

[48]  S. Lindquist,et al.  Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology , 2003, Science.

[49]  Susan Lindquist,et al.  Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein , 2003, Science.

[50]  J. Wendland PCR-based methods facilitate targeted gene manipulations and cloning procedures , 2003, Current Genetics.

[51]  Peter T Lansbury,et al.  Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. , 2003, Biochemistry.

[52]  V. Subramaniam,et al.  Dependence of α-synuclein aggregate morphology on solution conditions , 2002 .

[53]  Sebastian Doniach,et al.  Biophysical Properties of the Synucleins and Their Propensities to Fibrillate , 2002, The Journal of Biological Chemistry.

[54]  M. Wax,et al.  Synucleins in glaucoma: Implication of γ‐synuclein in glaucomatous alterations in the optic nerve , 2002 .

[55]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[56]  J. George,et al.  The synucleins , 2001, Genome Biology.

[57]  Makoto Hashimoto,et al.  β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.

[58]  J. Trojanowski,et al.  Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .

[59]  J Q Trojanowski,et al.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Lavedan The synuclein family. , 1998, Genome research.

[61]  David F. Clayton,et al.  The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.

[62]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[63]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[64]  P. V. van Zijl,et al.  Improved sensitivity of HSQC spectra of exchanging protons at short interscan delays using a new fast HSQC (FHSQC) detection scheme that avoids water saturation. , 1995, Journal of magnetic resonance. Series B.

[65]  R. Müller,et al.  Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. , 1995, Gene.

[66]  S. Nakajo,et al.  A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. , 1993, European journal of biochemistry.

[67]  Rodney Rothstein,et al.  Elevated recombination rates in transcriptionally active DNA , 1989, Cell.

[68]  S. Lindquist,et al.  The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. , 2008, Proceedings of the National Academy of Sciences of the United States of America.

[69]  C. Griesinger,et al.  Structural characterization of the intrinsically unfolded protein beta-synuclein, a natural negative regulator of alpha-synuclein aggregation. , 2007, Journal of molecular biology.

[70]  J. Trojanowski,et al.  Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. , 2006, Human molecular genetics.

[71]  Vladimir N Uversky,et al.  Forcing nonamyloidogenic beta-synuclein to fibrillate. , 2005, Biochemistry.

[72]  R. Nussbaum,et al.  Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. , 2005, American journal of human genetics.

[73]  C. Ross,et al.  Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[74]  M. Feany,et al.  Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. , 2005, Nature neuroscience.

[75]  J. Winderickx,et al.  Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast. , 2005, The FEBS journal.

[76]  J. Trojanowski,et al.  Beta-synuclein gene alterations in dementia with Lewy bodies. , 2004, Neurology.

[77]  M. Farrer,et al.  alpha-Synuclein promoter confers susceptibility to Parkinson's disease. , 2004, Annals of neurology.

[78]  S. Lindquist,et al.  Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. , 2003, Science.

[79]  E. Masliah,et al.  alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.

[80]  M. Wax,et al.  Synucleins in glaucoma: implication of gamma-synuclein in glaucomatous alterations in the optic nerve. , 2002, Journal of neuroscience research.

[81]  V. Subramaniam,et al.  Dependence of alpha-synuclein aggregate morphology on solution conditions. , 2002, Journal of molecular biology.

[82]  E. Masliah,et al.  beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. , 2001, Neuron.

[83]  J. Trojanowski,et al.  Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. , 2000, The American journal of pathology.